Clinical research progress of anti-angiogenic tyrosine kinase inhibitors in solid tumors
Angiogenesis plays a key role in the growth,local invasion and distant metastasis of a variety of solid tumors.At present,anti-angiogenesis drugs can be divided into three types:small-molecule multi-target,macromolecule single-target and endogenous pan-target angiogenesis inhibitors.Among them,small molecule anti-angiogenesis inhibitors mainly inhibit tumor angiogenesis by simultaneously or sequentially targeting multiple growth factors/pathways,and can effectively inhibit drug resistance generated by tumor cells.At the same time,small molecule anti-angiogenesis inhibitors have the advantages of good tissue permeability and convenient administration.At present,it has been widely used in the combination therapy of various solid tumors.This paper reviewed the targeted therapy of small molecule anti-angiogenic tyrosine kinase inhibitors and their clinical progress and safety in multiple solid tumors.
NETL
NSTL
万方数据
